Fudim M, White J, Pagidipati NJ, et al. - Given that the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) showed a neutral impact of once-weekly exenatide (EQW) on hospitalization for heart failure (hHF), with no differential treatment influence on major adverse cardiac events (MACE) by baseline heart failure (HF) status, researchers performed this prespecified analysis of the randomized controlled EXSCEL trial in order to determine the influences of EQW on secondary endpoints, as well as to know how recurrent hHF events were influenced by EQW among patients with type 2 diabetes with and without additional cardiovascular disease. They investigated the influences of EQW on all-cause mortality, each MACE component, first hHF and repeat hHF by baseline HF status (irrespective of ejection fraction). The presence of HF at baseline was found in 2,389 (16.2%) of overall 14,752 EXSCEL participants. Findings revealed good tolerability of EQW in patients with or without HF in EXSCEL, however, patients with baseline HF experienced attenuation in the benefits of EQW on decreasing all-cause death and first hospitalization for HF.